ARTICLE | Company News
Emergent BioSolutions cancer, hematology news
September 14, 2015 7:00 AM UTC
Emergent will spin out its biosciences business into a stand-alone, publicly traded company. The spinout will focus on oncology and hematology therapeutics and will receive $50-$70 million in cash fro...